A-01 Wilhelm Huisinga Physiologically-based pharmacokinetic/pharmacodynamic modelling, mathematical model reduction and a mechanistic interpretation of simple empirical models
|
A-02 Martin Bergstrand (1), Erik Söderlind (2), Ulf Eriksson (2), Werner Weitschies (3), Mats O. Karlsson (1) Semi-mechanistic modeling of absorption from extended release formulations - linking in vitro to in vivo
|
A-03 T. Eissing, J. Lippert, S. Willmann Investigation of the Influence of CYP3A4 Inhibition and Renal Impairment on Morphine and M6G Formation after Codeine Administration using Coupled Whole-Body PBPK Modelling
|
A-04 Pascal Chanu (1), Balaji Agoram (2), Rene Bruno (1) Mechanistic Models to Simulate Dose Response of IgE Suppression Following Dosing of Anti-IgE Monoclonal Antibodies
|
A-05 Julia Korell, Carolyn V. Coulter, Stephen B. Duffull Design of survival studies for red blood cells
|
A-06 Stephen Senn Some considerations concerning covariates in clinical trials
|
A-07 Akash Khandelwal, Kajsa Harling, E Niclas Jonsson, Andrew C Hooker, Mats O Karlsson Covariate Model Building Using Linear Approximations
|
A-08 Brigitte D. Lacroix(1,2), Lena E. Friberg(1) and Mats O. Karlsson(1) Evaluating the IPPSE method for PKPD analysis
|
A-09 Dalia Khachman, Celine M. Laffont and Didier Concordet You have problems to interpret VPC? Try VIPER!
|
A-10 B. Boulanger, A. Jullion & P. Lebrun Trial predictions vs. trial simulations in early clinical development: a framework to evaluate the predictive probability of success based on NONMEM outputs
|
A-11 Caroline Bazzoli, Sylvie Retout, France Mentré Design evaluation and optimisation in multi-response nonlinear mixed effect models with cost functions: application to the pharmacokinetics of zidovudine and its active metabolite
|
A-12 M. Delattre (1), R. Savic (2), R. Miller (3), M. O. Karlsson (4), M. Lavielle (5) Estimation of mixed hidden Markov models with SAEM. Application to daily seizures data.
|
A-13 Lay Ahyoung Lim (1), Raymond Miller (2), Kyungsoo Park (1) Dose-Response-Dropout Analysis for Somnolence in Pregabalin-treated Patients with Generalized Anxiety Disorder
|
A-14 Chao Zhang1, Paolo Denti1, Jan-Stefan van der Walt1,2, Ulrika SH Simonsson2, Gary Maartens1, Mats O.Karlsson2, Helen McIlleron1 Population Pharmacokinetics of Lopinavir/Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Children
|
A-15 Jeffrey S Barrett1, Sundararajan Vijayakumar2, Kalpana Vijayakumar2, Sarapee Hirankarn1, Bhuvana Jayaraman1, Erin Dombrowsky1, Mahesh Narayan1, Julia Winkler1,3, Marc Gastonguay3 Enhancing Methotrexate Pharmacotherapy in Children with Cancer: A Decision Support System Integrating Real-time PK/PD Modeling and Simulation with Patient Medical Records
|
A-16 Sarah C McLeay (1), Glynn A Morrish (1), Carl MJ Kirkpatrick (1) & Bruce Green (2) Exploring different body-size metric based dosing strategies for propofol in morbidly obese versus healthy weight subjects by modelling and simulation approach
|
A-17 Eugène Cox (1), D. Russell Wada (1), Nancy Zhang (1) & Frank Wiegand (2) Meta- Analysis of Retention Rates of Post-Marketing Trials to Compare Effectiveness of Second Generation Antiepileptic Drugs
|
A-18 Rocío Lledó-García, PhD1, Norman A. Mazer, MD, PhD2 and Mats O. Karlsson, PhD1 A mechanistic model of the steady-state relationship between HbA1c and average glucose levels in a mixed population of healthy volunteers and diabetic subjects
|
A-19 Jonathan L. French When and how should I combine patient-level data and literature data in a meta-analysis?
|
A-20 Camille Vong, Martin Bergstrand, Mats O. Karlsson Rapid sample size calculations for a defined likelihood ratio test-based power in mixed effects models
|
A-21 Lee-Kien Foo, Stephen Duffull D-optimal Adaptive Bridging Studies in Pharmacokinetics
|
A-22 Marc Lavielle (1), Hector Mesa (1), Kaelig Chatel (1), An Vermeulen (2) Mixture models and model mixtures with MONOLIX
|
A-23 Matthew M. Hutmacher Extending the Latent Variable Model to Non-Independent Longitudinal Dichotomous Response Data
|
A-24 Elodie L. Plan, Kristin E. Karlsson, Mats O. Karlsson Analysis Approaches Handling Both Symptomatic Severity and Frequency
|
A-25 S. Goutelle (1,2), L. Bourguignon (1,2), R.W. Jelliffe (3), J.E. Conte Jr (4,5), P. Maire (1,2) Mathematical modeling of pulmonary tuberculosis therapy: development of a first prototype model with rifampin
|
A-26 A. Russu (1), E. Marostica (1), G. De Nicolao (1), A.C. Hooker (2), I. Poggesi (3), R. Gomeni (3), S. Zamuner (3) Integrated model for clinical response and dropout in depression trials: a state-space approach
|
A-27 Petersson KJF (1), Vermeulen AM (2), Friberg LE (1) Predictions of in vivo prolactin levels from in vitro Ki values of D2 receptor antagonists using an agonist-antagonist interaction model.
|
A-28 Radojka Savic (1,2), Aurélie Barrail-Tran (3) , Xavier Duval (1,3), Georges Nembot (1,3), Xavière Panhard (1), Diane Descamps (3), Bernard Vrijens (4), France Mentré (1,3), Cécile Goujard (3), Anne-Marie Taburet (3) and the ANRS 134 study group Adherence and Population Pharmacokinetics of Atazanavir in Naïve HIV-Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing
|